AbCellera Biologics Inc. Other Non-Current Liabilities
AbCellera Biologics Inc. (ABCL) had Other Non-Current Liabilities of $9.71 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Other Liabilities, Noncurrent $9.71M.
- 2026-03-31: Other Liabilities, Noncurrent $11.32M.
- 2025-12-31: Other Liabilities, Noncurrent $10.38M; Other Liabilities, Noncurrent as first filed $4.77M.
- 2025-09-30: Other Liabilities, Noncurrent $1.39M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $9.71M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $11.32M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $10.38M 10-Q · filed 2026-08-05 | $4.77M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.39M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.56M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.62M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $7.17M 10-K · filed 2026-02-24 | $1.47M 10-K · filed 2025-02-27 |
| 2024-09-30 | $1.52M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $6.35M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $5.74M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $5.91M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $5.05M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $2.33M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $2.96M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $3.09M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $2.86M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $2.98M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $3.43M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.73M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $1.70M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.66M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $931.00K 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $6.62M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |